Estimating and Projecting Efficacy of Monoclonal Antibodies Against Respiratory Syncytial Virus Beyond Clinical Trial Periods.

Wang D, Lang JC, Kura K, Chen YH

Open source

DOI
10.3390/vaccines14090737
Published
2026 Aug 26
Container
Vaccines
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/vaccines14090737,
  title = {Estimating and Projecting Efficacy of Monoclonal Antibodies Against Respiratory Syncytial Virus Beyond Clinical Trial Periods.},
  author = {Wang D and Lang JC and Kura K and Chen YH},
  year = {2026},
  journal = {Vaccines},
  doi = {10.3390/vaccines14090737},
  url = {https://doi.org/10.3390/vaccines14090737}
}

RIS

TY  - JOUR
TI  - Estimating and Projecting Efficacy of Monoclonal Antibodies Against Respiratory Syncytial Virus Beyond Clinical Trial Periods.
AU  - Wang D
AU  - Lang JC
AU  - Kura K
AU  - Chen YH
PY  - 2026
JO  - Vaccines
DO  - 10.3390/vaccines14090737
UR  - https://doi.org/10.3390/vaccines14090737
ER  - 

APA

D, W., JC, L., K, K., & YH, C. (2026). Estimating and Projecting Efficacy of Monoclonal Antibodies Against Respiratory Syncytial Virus Beyond Clinical Trial Periods.. Vaccines. https://doi.org/10.3390/vaccines14090737

Source records